Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 83730-53-4 Chemical Structure| 83730-53-4

Structure of BSO
CAS No.: 83730-53-4

Chemical Structure| 83730-53-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

L-Buthionine Sulfoximine is a potent inhibitor of GSH synthesis.

Synonyms: L-BSO; NSC 326231; L-Buthionine sulfoximine

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Feng, Jiukang ; Liu, Hui ; Jiang, Kewei ; Gong, Xinyu ; Huang, Rong ; Zhou, Chao , et al.

Abstract: Aims: Idiopathic pulmonary fibrosis (IPF) is a disease associated with aging, where increased oxidative stress accelerates the progression of pulmonary fibrosis (PF). The specific mechanisms through which oxidative stress intensifies PF are still not fully understood. Materials and methods: In this study, we used bleomycin (BLM)-induced PF mouse model and TGF-β-induced collagen deposition cells for in vivo and in vitro experiments, respectively. Additionally, we employed BSO, a glutathione synthesis inhibitor, to induce excess reactive oxygen species (ROS). Key findings: Our findings revealed that heightened ROS production significantly exacerbated PF development in mice and increased collagen deposition in A549 cells. We also showed that cellular senescence was further intensified by the combined treatment of BSO with BLM or TGF-β, as indicated by the increased levels of p53 and p21, along with an increase in β-galactosidase-positive cells. Moreover, inflammatory responses, including inflammatory cells, inflammatory cytokines, and ROS levels were dramatically increased with the BSO and BLM or TGF-β combination. Mechanistically, we found that NLRP3 inflammasome was activated more significantly by the combined treatments of BSO with BLM or TGF-β. Inhibition of NLRP3 ameliorated the aging-related phenotype and reduced p53 and p21 expression. Furthermore, we showed that N-acetylcysteine (NAC) treatment significantly attenuated BLM or BLM plus BSO-enhanced PF in vivo. Significance: Our study demonstrates that elevated ROS levels contribute to the development of PF via NLRP3-mediated cellular senescence. We also provide that targeting oxidative stress might be an effective strategy for treating PF.

Keywords: Pulmonary fibrosis ; Senescence ; ROS ; NLRP3 ; Bleomycin

Purchased from AmBeed:

Alternative Products

Product Details of BSO

CAS No. :83730-53-4
Formula : C8H18N2O3S
M.W : 222.31
SMILES Code : N[C@@H](CCS(CCCC)(=O)=N)C(O)=O
Synonyms :
L-BSO; NSC 326231; L-Buthionine sulfoximine
English Name :(2S)-2-Amino-4-(butylsulfonimidoyl)butanoic acid
MDL No. :MFCD00067000
InChI Key :KJQFBVYMGADDTQ-CVSPRKDYSA-N
Pubchem ID :119565

Safety of BSO

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW264.7 cells 0.5 mM overnight Investigate the effect of BSO on NF-κB inhibition J Agric Food Chem. 2020 Jun 3;68(22):6154-6160.
transformed astrocytes 10 µM 24 h To assess the effect of glutathione depletion on cell number, results showed that male cells were more sensitive to glutathione depletion. Med. 2022 Nov 11;3(11):792-811.e12.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MBCUCP1 KO mice Intraperitoneal injection 0.445 mg/g/d 5 weeks BSO treatment significantly reduced serum glutathione levels and attenuated insulin tolerance Cell. 2024 May 9;187(10):2359-2374.e18
Mice MLL-AF9 AML model I.p. and in drinking water 2.23 mg/kg + 4.45 mg/ml Twice daily for 4 days BSO treatment did not significantly improve the survival of AML-bearing mice Cell Metab. 2020 Sep 1;32(3):391-403.e6
Mice C57BL/6 mice Intraperitoneal injection 100 mg/kg Single dose, 2 hours duration BSO treatment increased mitochondrial content in LSK and HSC populations, mimicking LPS and S. typhimurium-induced ROS elevation. Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24610-24619
Mice GSH-depleted model Intraperitoneal injection 650 mg/kg Single dose, lasting 24 hours To evaluate the effect of BSO on psoralen and isopsoralen-induced hepatotoxicity, results showed that BSO significantly enhanced the hepatotoxicity of psoralen Molecules. 2017 Sep 4;22(9):1451
BALB/c nu/nu athymic mice HCC827 cell-derived xenograft model Intraperitoneal injection 450 mg/kg Every 2 days, until the end of the experiments Investigated the effect of BSO on ALDH1A1-induced erlotinib resistance, finding that BSO could reverse ALDH1A1-induced erlotinib resistance. Theranostics. 2019 Sep 23;9(24):7122-7139
Mice FVB and MT overexpression transgenic mice Drinking water 30 mM 2 weeks To evaluate the effects of BSO on cardiac function, oxidative stress, ER stress, and myocardial ultrastructure, results showed that BSO significantly reduced cardiac function, increased oxidative stress and ER stress, and caused changes in myocardial ultrastructure, while MT overexpression reversed these effects. J Mol Cell Cardiol. 2009 Aug;47(2):228-37.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.50mL

0.90mL

0.45mL

22.49mL

4.50mL

2.25mL

44.98mL

9.00mL

4.50mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories